SCHEMBL4821057

SCHEMBL4821057

O=C(O)P(c1ccccc1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.45
TDP1 Q9NUW8 3/20 0.45
TSHR P16473 3/20 0.43
MAPT P10636 2/20 0.43
POLB P06746 1/20 0.43
PARP1 P09874 1/20 0.43
CYP2C19 P33261 1/20 0.43
RECQL P46063 1/20 0.43
BLM P54132 1/20 0.43
PMP22 Q01453 1/20 0.43
HSD17B10 Q99714 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CES1 P23141 4/20 0.41
CES2 O00748 3/20 0.41
ALDH1A1 P00352 2/20 0.41
ALOX15 P16050 2/20 0.41
DAO P14920 1/20 0.41
NAPRT Q6XQN6 1/20 0.41
ESR1 P03372 3/20 0.40
ESR2 Q92731 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzene SCHEMBL28010663 1.00 CYP3A4 (0.45) CYP3A4TDP1TSHRMAPTPOLB
Ammonia Solution, Strong SCHEMBL31339447 0.97 CYP3A4 (0.43) CYP3A4TDP1TSHRMAPTPOLB
SCHEMBL28008458 0.86 KMO (0.50) CYP3A4ESR1PTPN1MEN1KMT2A
SCHEMBL3155593 0.82 CYP3A4 (0.45) CYP3A4TDP1TSHRMAPTPOLB
SCHEMBL7532752 0.82 CYP3A4 (0.45) CYP3A4TDP1TSHRMAPTPOLB
SCHEMBL5034105 0.78 CES2 (0.42) CYP3A4TDP1TSHRMAPTPOLB
SCHEMBL8859112 0.78 CYP3A4 (0.41) CYP3A4TDP1TSHRMAPTPOLB
SCHEMBL8666770 0.78 CYP3A4 (0.41) CYP3A4TDP1TSHRMAPTPOLB
SCHEMBL28702640 0.77 CYP3A4 (0.45) CYP3A4TDP1TSHRMAPTPOLB
SCHEMBL18204065 0.76 CES2 (0.46) CYP3A4TDP1TSHRMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250073692-A1 PROCESS FOR PREPARING LINEAR ALPHA-OLEFIN BY OLIGOMERIZATION OF ETHYLENE NANJING CHEMISTRY NEW ENERGY TECHNOLOGY CO., LTD. (CN) 2025-03-06 US claimed
US-20250073692-A1 PROCESS FOR PREPARING LINEAR ALPHA-OLEFIN BY OLIGOMERIZATION OF ETHYLENE NANJING CHEMISTRY NEW ENERGY TECHNOLOGY CO., LTD. (CN) 2025-03-06 US disclosed
US-7368604-B2 Method for the production of acylphosphine oxides BASF AKTIENGESELLSCHAFT (DE) 2008-05-06 US disclosed
EP-1546163-B1 METHOD FOR THE PRODUCTION OF ACYLPHOSPHINE OXIDES BASF AG (DE) 2006-07-12 EP disclosed
US-20060052636-A1 Method for the production of acylphosphine oxides BASF AKTIENGESELLSCHAFT (DE) 2006-03-09 US disclosed
EP-1546163-A1 METHOD FOR THE PRODUCTION OF ACYLPHOSPHINE OXIDES BASF AKTIENGESELLSCHAFT (DE) 2005-06-29 EP disclosed
WO-2004029063-A1 METHOD FOR THE PRODUCTION OF ACYLPHOSPHINE OXIDES BASF AKTIENGESELLSCHAFT (DE) 2004-04-08 WO disclosed
US-5808121-A COORDINATION CATALYSTS BP CHEMICALS LIMITED (GB) 1998-09-15 US disclosed
US-5525566-A POLYMERIZATION CATALYST FOR ETHYLENE-CARBON MONOXIDE COPOLYMER BP CHEMICALS LIMITED (GB) 1996-06-11 US disclosed
EP-0616848-A1 Catalyst compositions BP Chemicals Limited (GB) 1994-09-28 EP disclosed
US-3728366-A LIQUID/LIQUID EXTRACTION OF COBALT VALUES SHELL OIL CO 1973-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052636-A1 Method for the production of acylphosphine oxides AGPAT5, PNPO, PHOSPHO1 CYP3A4 588/4885TDP1 1967/4885TSHR 3990/4885
US-20250073692-A1 PROCESS FOR PREPARING LINEAR ALPHA-OLEFIN BY OLIGOMERIZATION OF ETHYLENE EDF1, ELL, EEF1D CYP3A4 797/4885TDP1 3485/4885TSHR 3718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.